Global Type 2 Diabetes - Competitive Landscape and Clinical Trial Analysis, 2026 | Oral GLP-1s, Multi-Agonists, and RNAi Drive Pipeline Investment and Partnership Opportunities
Dublin, Oct. 14, 2026 (GLOBE NEWSWIRE) -- "Type 2 Diabetes - Competitive Landscape and Clinical Trial Analysis, 2026" has been added to ResearchAndMarkets.com's offering.
The report provides a global assessment of the Type 2 diabetes competitive landscape, covering more than 200 companies and 200 marketed, clinical-stage, preclinical, and inactive drugs. It evaluates therapies by product type, development stage, route of administration, and molecule type while examining clinical trial activity, company strategies, licensing agreements, acquisitions, and research collaborations.
Type 2 Diabetes Overview
Type 2 diabetes mellitus is a chronic metabolic disorder associated with insulin resistance, progressive pancreatic ?-cell dysfunction, and persistent hyperglycemia. Disease progression is influenced by impaired insulin action in skeletal muscle, adipose tissue, and the liver, as well as altered incretin signaling, glucagon excess, inflammation, and abnormal renal glucose handling.
Clinical management is increasingly individualized according to glycemic status, body weight, cardiovascular and kidney risk, comorbidities, safety considerations, and patient preferences. Treatment options include metformin, GLP-1 receptor agonists, dual GIP/GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, sulfonylureas, thiazolidinediones, and insulin. Current treatment strategies emphasize therapies offering cardiovascular, renal, and weight-related benefits in addition to glycemic control.
Recent Type 2 Diabetes Pipeline and Market Developments
Marketed and Emerging Type 2 Diabetes Therapies
The report profiles established products and emerging candidates from leading pharmaceutical and biotechnology companies. Marketed therapies include Ozempic from Novo Nordisk and INVOKANA from Janssen Pharmaceuticals. Orforglipron, developed by Eli Lilly, is an oral, once-daily small-molecule GLP-1 receptor agonist authorized by the UK MHRA in August 2026 for adults with insufficiently controlled Type 2 diabetes.
Late-stage pipeline candidates include RAY1225 from Guangdong Raynovent Biotech, a once-every-two-weeks GLP-1 and GIP receptor dual agonist in Phase III development, and CagriSema, Novo Nordisk's once-weekly fixed-dose combination of cagrilintide and semaglutide.
Other differentiated programs include ALN-4324, a long-acting RNA interference therapy designed to improve insulin sensitivity; TQF3250, an oral small-molecule biased GLP-1 receptor agonist; IBI3032, an oral GLP-1R agonist in Phase I trials; and NRDN-101, a preclinical candidate targeting calcium homeostasis in pancreatic ?-cells.
Competitive and Clinical Trial Analysis
The report compares companies by therapy type and development stage and assesses collaboration, partnering, licensing, acquisition, and company-academic activity. Its clinical trial analysis covers trial status, development phase, therapeutic area, participant age, study completion year, endpoint status, allocation, interventional model, masking, and enrollment status.
Sponsor and geographic analysis evaluates leading trial sponsors, development stages, country-level clinical activity, and therapy distribution by market. The coverage also identifies inactive assets, unmet needs, emerging technologies, recent drug development trends, and regulatory designations granted to approved and investigational therapies.
Selected Companies Covered
Selected Products Covered
By integrating Type 2 diabetes pipeline analysis, clinical trial intelligence, competitive benchmarking, and transaction activity, the report supports pharmaceutical companies, investors, researchers, and strategic decision-makers seeking to evaluate innovation, partnership opportunities, and future market development.
Key Topics Covered:
Introduction
Executive Summary
Type 2 Diabetes: Overview
Type 2 Diabetes -Analytical Perspective: In-depth Commercial Assessment
Competitive Landscape
Type 2 Diabetes: Company and Product Profiles (Marketed Therapies)
Eli Lilly and Company
Orforglipron
Type 2 Diabetes: Company and Product Profiles (Pipeline Therapies)
Late Stage Products (Phase III)
Guangdong Raynovent Biotech Co., Ltd
RAY1225
Mid Stage Products (Phase II)
Alnylam Pharmaceuticals
ALN-432
Early Stage Products (Phase I)
Chia Tai Tianqing Pharmaceutical Group
TQF3250
Preclinical Stage Products
Discovery Stage Products
Unknown Stage Products
Therapeutic Assessment
Clinical Trial Assessment
Clinical Trial Analysis
Clinical Trial Design Analysis
Sponsor and Geographical Analysis
Inactive Products
Type 2 Diabetes- Unmet needs
Type 2 Diabetes - Market drivers and barriers
Appendix
List of Tables [24]
List of Figures [24]
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this report visit https://www.researchandmarkets.com/r/kykjbs
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.